Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and neurological disorders [5] - The company is advancing a portfolio of therapeutics aimed at addressing significant unmet medical needs across various diseases, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation [5] Product Development - Artelo's lead product, ART26.12, is a Fatty Acid Binding Protein 5 (FABP5) inhibitor, which is being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) [4] - A Phase 1 Single Ascending Dose study of ART26.12 in healthy volunteers is nearing completion, with data expected in Q2 2025 [3] - The inhibition of FABP5 has shown potential therapeutic activity in models of neuropathic pain, osteoarthritis, cancer, and cancer bone pain [3] Upcoming Events - Myles Osborn, Lead Medicinal Chemist at Artelo, will present at the 4th ACE Drug Discovery Summit on April 3, 2025, discussing the impact of FABP5 inhibition across various disease models [2][6] - The presentation will provide insights into the consensus mechanisms of FABP5 inhibition and its implications for therapeutic development [2] Industry Context - The 4th ACE Drug Discovery Summit serves as a platform for global scientists and researchers to discuss advancements and challenges in drug discovery, emphasizing collaboration and innovation in the pharmaceutical and technology sectors [6]